The Serum Levels of Resistin and Its Relationship with Other Proinflammatory Cytokines in Patients with Alzheimer’s Disease
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: The present study aims to analyze the levels of resistin, tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-18, and C-reactive protein (CRP) in patients with Alzheimer’s disease (AD) and also investigate a potential relationship between resistin levels and TNF-α, IL-1β, IL-6, IL-18, and CRP levels in patients with AD. Methods: The study included fifty patients with AD and 30 healthy controls with normal cognitive functions. The serum resistin, TNF-α, IL-1β, IL-6, IL-18, and CRP levels were assessed. We performed a Mini-Mental State Examination (MMSE) to evaluate the general cognitive performance. Results: The mean serum resistin, IL-1β, IL-18, and TNF-α levels were significantly higher in patients with AD compared with the controls (p=0.026, p=0.002, p=0.003, and p=0.038, respectively). The IL-6 and CRP levels did not differ between the groups (p=0.874 and p=0.941). The resistin levels were positively correlated with the levels of CRP and IL-18 (r=0.526, p＜0.001; r=0.402, p=0.004, respectively). MMSE scores and inflammatory markers were not correlated (p＞0.05 for all). Conclusion: Serum resistin levels were significantly increased and correlated with some inflammatory markers in AD patients, suggesting that resistin might play a role in the inflammatory process of AD.
Abstract
Objective: The present study aims to analyze the levels of resistin, tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-18, and C-reactive protein (CRP) in patients with Alzheimer’s disease (AD) and also investigate a potential relationship between resistin levels and TNF-α, IL-1β, IL-6, IL-18, and CRP levels in patients with AD. Methods: The study included fifty patients with AD and 30 healthy controls with normal cognitive functions. The serum resistin, TNF-α, IL-1β, IL-6, IL-18, and CRP levels were assessed. We performed a Mini-Mental State Examination (MMSE) to evaluate the general cognitive performance. Results: The mean serum resistin, IL-1β, IL-18, and TNF-α levels were significantly higher in patients with AD compared with the controls (p=0.026, p=0.002, p=0.003, and p=0.038, respectively). The IL-6 and CRP levels did not differ between the groups (p=0.874 and p=0.941). The resistin levels were positively correlated with the levels of CRP and IL-18 (r=0.526, p＜0.001; r=0.402, p=0.004, respectively). MMSE scores and inflammatory markers were not correlated (p＞0.05 for all). Conclusion: Serum resistin levels were significantly increased and correlated with some inflammatory markers in AD patients, suggesting that resistin might play a role in the inflammatory process of AD.
참고문헌 (33)
- Choi DY, "Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease", Brain Res Bull, 87, pp.144~153 (2012)
- "World alzheimer report 2014: Dementia and risk reduction-an analysis of protective and modifiable factors" (2014)[URL]
- Kizilarslanoğlu MC, "Alzheimer disease, inflammation, and novel inflammatory marker: resistin", Turk J Med Sci, 45, pp.1040~1046 (2015)
- Alam Q, "Inflammatory process in Alzheimer's and Parkinson's diseases : Central role of cytokines", Curr Pharm Des, 22, pp.541~548 (2016)
- Cacabelos R, "Brain interleukin-1 beta in Alzheimer's disease and vascular dementia", Methods Find Exp Clin Pharmacol, 16, pp.141~151 (1994)
- Sutinen EM, "Pro-inflammatory interleukin-18 increases Alzheimer's diseaseassociated amyloid- production in human neuron-like cells", J Neuroinflammation, 9, pp.199~ (2012)
- Zhang ZG, "Inflammation in Alzheimer's disease and molecular genetics : Recent update", Arch Immunol Ther Exp(Warsz), 63, pp.333~344 (2015)
- Filková M, "The role of resistin as a regulator of inflammation : Implications for various human pathologies", Clin Immunol, 133, pp.157~170 (2009)
- Pang SS, "Role of resistin in inflammation and inflammation-related diseases", Cell Mol Immunol, 3, pp.29~34 (2006)
- Konrad A, "Resistin is an inflammatory marker of inflammatory bowel disease in humans", Eur J Gastroenterol Hepatol, 19, pp.1070~1074 (2007)
- Senolt L, "Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum", Ann Rheum Dis, 66, pp.458~463 (2007)
- Kocabas H, "The serum levels of resistin in ankylosing spondylitis patients : a pilot study", Rheumatol Int, 32, pp.699~702 (2012)
- Axelsson J, "Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance", Kidney Int, 69, pp.596~604 (2006)
- Reilly MP, "Resistin is an inflammatory marker of atherosclerosis in humans", Circulation, 111, pp.932~939 (2005)
- Leung YY, "Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study", Alzheimers Dement(Amst), 1, pp.339~348 (2015)
- Hu WT, "Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment", Acta Neuropathol, 119, pp.669~678 (2010)
- Kim BJ, "Adipocytokines and ischemic stroke : differential associations between stroke subtypes", J Neurol Sci, 312, pp.117~122 (2012)
- Xiao-Liu Dong, "Serum Resistin Levels May Contribute to an Increased Risk of Acute Cerebral Infarction", Molecular Neurobiology, 54(3), pp.1919~1926 (2017), Springer Nature[DOI]
- Zhang DQ, "Remarkably increased resistin levels in anti-AChR antibodypositive myasthenia gravis", J Neuroimmunol, 283, pp.7~10 (2015)
- Chai NC, "Ictal adipokines are associated with pain severity and treatment response in episodic migraine", Neurology, 84, pp.1409~1418 (2015)
- Savas S, "No relationship between lipoproteinassociated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease", Exp Gerontol, 77, pp.1~6 (2016)
- Suk Ling Ma, "Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer’s Disease", Clinical Psychopharmacology and Neuroscience, 9(2), pp.54~66 (2011), 대한정신약물학회
- Varnum MM, "The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain", Arch Immunol Ther Exp(Warsz), 60, pp.251~266 (2012)
- Tan ZS, "Inflammatory markers and the risk of Alzheimer disease : the Framingham study", Neurology, 68, pp.1902~1908 (2007)
- Malaguarnera L, "Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia", Neuropathology, 26, pp.307~312 (2006)
- Dursun E, "The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease", J Neuroimmunol, 283, pp.50~57 (2015)
- Lanzrein AS, "Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin", Alzheimer Dis Assoc Disord, 12, pp.215~227 (1998)
- Song IU, "Relationship between the hs-CRP as non-specific biomarker and Alzheimer's disease according to aging process", Int J Med Sci, 12, pp.613~617 (2015)
- Noble JM, "Association of C-reactive protein with cognitive impairment", Arch Neurol, 67, pp.87~92 (2010)
- Swardfager W, "A meta-analysis of cytokines in Alzheimer's disease", Biol Psychiatry, 68, pp.930~941 (2010)
- Parker DC, "Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease", Int J Geriatr Psychiatry, 28, pp.149~154 (2013)
- Yasutake C, "Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia", Eur Arch Psychiatry Clin Neurosci, 256, pp.402~406 (2006)
- Wu YY, "Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer's disease", Dement Geriatr Cogn Dis Extra, 5, pp.424~434 (2015)